Abstract

BackgroundGlobally, an estimated 8.1 million children under 5 years die annually in developing countries. Ensuring essential medicines are accessible and affordable to the population is key to saving lives. This study investigated accessibility, availability and affordability of a basket of priority medicines for children under 5 years in public and private healthcare sector pharmacies in the eThekwini Metropolitan area in Durban, South Africa.MethodsThe WHO/HAI survey tool for assessing medicine prices, availability and affordability was adapted and employed for a basket of WHO Priority life-saving medicines for children under 5 years. Six district hospitals in the north, south and central eThekwini Metropolitan were selected as major facility reference points and for data collection and pharmacies within a 5 km radius from each major facility were also invited to participate in the study, as outlined in the WHO/HAI tool methodology. Of the 58 pharmacies selected, a total of 27 pharmacies from both private and public healthcare sectors agreed to participate and were surveyed, representing a 47% response rate. Data was analysed using Microsoft excel.ResultsAll participating pharmacies (and hence the selected basket of priority medicines at these facilities) were deemed accessible. Overall the public sector had more medicines available on the shelf (averaging 64%) than the private sector (48%) which had more medicines available on order (84%). At least one medicine for each of the eight (8) conditions was available at both sectors which meant patients could be treated for these conditions. Medicines for priority conditions (except HIV, which was a 28-day course) were deemed affordable as these regimens were obtainable within a day’s wage for the lowest paid unskilled worker. Priority medicines for children under 5 years were more available and more affordable in the public sector.ConclusionThe basket of WHO essential medicines for priority conditions for children under 5 years were accessible, available and affordable in the eThekwini Metropolitan areas. This was the first study in eThekwini to determine access to the WHO basket of priority medicines for children and can be scaled-up to a national study to provide a holistic comparison of these medicines in the country, and also for global comparison.

Highlights

  • An estimated 8.1 million children under 5 years die annually in developing countries

  • The peripheral/rural areas of eThekwini fell out of the geographical area for this study and access to priority medicines for children under 5 years would need to be evaluated in these areas in a separate study, which would be useful for comparison

  • The availability of vaccines in the public and private sector was 65% in this study, it is worth noting that the remaining 35% accounted for travel vaccines, which are available from travel clinics and private practitioners, which were not investigated in this study

Read more

Summary

Introduction

An estimated 8.1 million children under 5 years die annually in developing countries. This study investigated accessibility, availability and affordability of a basket of priority medicines for children under 5 years in public and private healthcare sector pharmacies in the eThekwini Metropolitan area in Durban, South Africa. Access to medicines is crucial in the Mahadeo et al Journal of Pharmaceutical Policy and Practice (2022) 15:2 fulfilment of the human right to the highest attainable standard of health [2], yet globally millions of people go without essential life-saving treatments due to numerous barriers. Subscribe to these goals as they move towards achieving Universal Health Coverage (UHC) which requires adequate access to safe, effective, affordable and quality medicines and vaccines [1, 5]. According to the World Health Organisation (WHO), a well-functioning healthcare system ensures equitable access to essential medicines, vaccines and technologies that are of assured quality, safety, and efficacy and which are costeffective [7]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call